Sep 18 2014

Americord Backs Another Cord Blood Clinical Trial

Posted by admin

Research explores the benefits of using autologous cord blood stem cells for children with Cerebral Palsy

New York – September 18, 2014 – Americord announced today that it has provided funding to support a clinical trial investigating the efficacy of autologous umbilical cord blood for the treatment of pediatric patients with cerebral palsy.

This trial is being conducted under the direction of an internationally renowned expert in umbilical cord blood transplantation. The purpose is to determine whether infusions of a child’s own cord blood can lessen the symptoms of cerebral palsy. The goal of the trial explores the potential of discovering how cord blood could be used for other purposes, including reducing inflammation in the brain and producing new hormones to repair damaged brain cells.

“This research for children with cerebral palsy is truly exciting,” said Americord CEO Martin Smithmyer. “We will be following this trial with great interest and we are thrilled to provide funding to help support it.” Americord’s funding has been made through its corporate giving program, which was established to support research focused on the therapeutic uses of stem cells from umbilical cord blood, cord tissue, and placenta tissue.

< Back to Blog
Category: Press